Suburban Detroit Dentist Settles Claims Against Him Involving Violations Of Controlled Substances Act
Contact: Public Information Officer
Number: (313) 234-4310
DETROIT - Marc R. Kamp of Bloomfield Hills, Michigan has agreed to pay $125,000, to settle civil claims against him under the Controlled Substances Act, announced Barbara McQuade, United States Attorney for the Eastern District of Michigan, and Robert L. Corso, Special Agent in Charge of the U.S. Drug Enforcement Administration's Detroit Field Division.
The resolution, which was agreed to by the parties without the filing of a lawsuit, resolves the government's claims that Dr. Kamp, 54, repeatedly violated the Controlled Substances Act by writing prescriptions for controlled substances, including hydrocodone, alprazolam and diazepam, that were not intended for a legitimate medical purpose. The settlement indicated that, between May, 2009, and September, 2013, Dr. Kamp wrote hundreds of such improper prescriptions. Among the patients who received these unnecessary prescriptions were at least two Birmingham Public Schools bus drivers.
Dr. Kamp also settled government claims that he falsified applications for his DEA registration in both 2009 and 2012, by failing to indicate that his state dental license had in the past been suspended. In the 2009 application, he failed to report that his dental license had been suspended for six days in August, 2009, a result of a felony ethnic intimidation conviction. Again in 2012, Dr. Kamp failed to report that his license had again been suspended - for four days in January, 2011 -- for practicing dentistry during his August 2009 suspension. Earlier this year, while facing administrative action by the DEA to revoke his controlled substances registration, Dr. Kamp voluntarily surrendered that registration. It is believed that he still holds a state license to practice dentistry.
The Controlled Substances Act provides civil penalties for a number of statutory violations, including the improper writing or filling of controlled substance prescriptions, and falsification of applications for DEA registrations. The case was investigated by DEA Detroit's Diversion Group.
